Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R. Del Re M, et al. Among authors: palleschi m. ESMO Open. 2022 Feb;7(1):100381. doi: 10.1016/j.esmoop.2022.100381. Epub 2022 Feb 4. ESMO Open. 2022. PMID: 35131649 Free PMC article. No abstract available.
Are we ready to use TMB in breast cancer clinical practice?
Ravaioli S, Limarzi F, Tumedei MM, Palleschi M, Maltoni R, Bravaccini S. Ravaioli S, et al. Among authors: palleschi m. Cancer Immunol Immunother. 2020 Oct;69(10):1943-1945. doi: 10.1007/s00262-020-02682-w. Epub 2020 Jul 28. Cancer Immunol Immunother. 2020. PMID: 32725361 Free PMC article.
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience.
Palleschi M, Maltoni R, Ravaioli S, Vagheggini A, Mannozzi F, Fanini F, Pirini F, Tumedei MM, Barzotti E, Cecconetto L, Sarti S, Manunta S, Possanzini P, Fedeli A, Curcio A, Altini M, De Giorgi U, Rocca A, Bravaccini S. Palleschi M, et al. Diagnostics (Basel). 2020 Aug 8;10(8):573. doi: 10.3390/diagnostics10080573. Diagnostics (Basel). 2020. PMID: 32784518 Free PMC article.
Corrigendum to "The cyclin-dependent kinases pathway as a target for prostate cancer treatment: Rationale and future perspectives" [Crit. Rev. Oncol. Hematol. 157 (January) (2021) 103199].
Brighi N, Conteduca V, Lolli C, Gurioli G, Schepisi G, Palleschi M, Mariotti M, Casadei C, De Giorgi U. Brighi N, et al. Among authors: palleschi m. Crit Rev Oncol Hematol. 2021 Aug;164:103401. doi: 10.1016/j.critrevonc.2021.103401. Epub 2021 Jul 16. Crit Rev Oncol Hematol. 2021. PMID: 34275720 No abstract available.
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R. Del Re M, et al. Among authors: palleschi m. ESMO Open. 2021 Oct;6(5):100231. doi: 10.1016/j.esmoop.2021.100231. Epub 2021 Sep 9. ESMO Open. 2021. PMID: 34509802 Free PMC article.
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib.
Del Re M, Crucitta S, Omarini C, Bargagna I, Mongillo M, Palleschi M, Stucci S, Meattini I, D'Onofrio R, Lorenzini G, Biondani P, De Giorgi U, Porta C, Livi L, Natalizio S, Fontana A, Giontella E, Angelini L, Fogli S, Danesi R. Del Re M, et al. Among authors: palleschi m. Breast. 2022 Dec;66:157-161. doi: 10.1016/j.breast.2022.10.005. Epub 2022 Oct 15. Breast. 2022. PMID: 36283134 Free PMC article.
78 results